Replies to Post #62493 onNorthWest Biotherapeutics Inc (NWBO)

Replies to #62493 on NorthWest Biotherapeutics Inc (NWBO)

05/21/16 5:42 AM

Nice post, Brad. But don't expect AF to accept the hard truth that there is a moral aspect to what he is doing which extends to moral responsibility for helping to delay availability of life extending or even life saving treatment, or for discouraging individual patients from treatments that could have helped them. That's way too fine a line for a guy like AF to understand, and in any case he thinks what he is doing is helping to stop any capital from being allocated to treatments which he has decided are not going to work. "What if you are wrong" is a difficult question which he will never be willing to entertain - he'd have to find a different career if he did.

DoGood_DoWell

05/21/16 5:57 AM

#62495 RE: notbrad #62493

notbrad Saturday, 05/21/16 04:05:09 AM
Re: Adam_Feuerstein post# 62376
Post # of 62494

Adam, here is some BS-free analysis of your work. You using your bully-pulpit in your writings has 2 insidious effects. You probably know that, but somewhere along the way you sold your soul and thus are able to sleep well at night:

1. The US is probably the only country where there is so much risk-capital going into innovative drug companies. That is why the US is by far the leader in new break-through medical technologies. By passing judgement on clinical trials, where even the sponsor, participants and regulators are blinded (where you couldn't possibly know more than they do), you drive down the stock price and make it more expensive for these companies to raise money to complete their work. This also drives away potential investors who may otherwise take risks because they know that the market is rigged. The ultimate effect is that early stage companies end up spending more than they otherwise have to because all the negative "news" from you from ends up raising the cost of capital. It slows down the trial process and probably contributes to higher drug prices when approved.

2. Secondly, your judgement on drugs still in the clinical trial phase (especially when you don't know more than the sponsors, investigators and regulators) also drives away potential trial participants. The affect: a patient who could have potentially benefited from the treatment probably dies early. Slow enrollment means longer trials and delayed time-to-market where is can potentially benefit thousands more.

Now do you understand where we are coming from when we criticize you?

Great post.

I will add:

1b. Your false criticism has been used in ambulance chaser legal filings causing the diversion of time and resources investors intended the company use to fund science and treat patients so we consider it theft